Narrow Your Results

Strategy

Sections

Keywords

Places

Gray Ratings

Showing 1 - 6 of 6 Results for "CD4 count"

Results

Tuberculosis
Further research is needed to determine the appropriate timing of initiating ART for TB/HIV co-infected patients. Studies conflict with regard to timing of TB therapy and ART for those patients with CD4 counts below 200. Studies also conflict with regard to timing for ART for patients with extra-pulmonary TB.
Tuberculosis
1 study
High ART coverage may reduce the number of new and recurrent TB cases.
Tuberculosis
2 studies Gray IIIb TB, treatment Malawi, Zimbabwe
Isoniazid preventative therapy can reduce the incidence of active TB and increase survival among people living with HIV.
Tuberculosis
7 studies Gray I, II, IIIa, IIIb TB, antiretrovirals, co-infection, screening, treatment Botswana, Brazil, South Africa, Tanzania
Initiating HIV treatment before or during TB therapy can reduce the incidence of TB and increase patient survival for those living with HIV, including for patients with XDR TB.
Tuberculosis
8 studies Gray II, IIIa, IIIb, IV HAART, HIV testing, TB, antiretrovirals, treatment Ethiopia, South Africa, Spain, Thailand
Active case finding increases TB detection, particularly in sub-Saharan Africa where HIV is driving the epidemic.
Tuberculosis
4 studies Gray IIIb, V TB, counseling, screening, testing India, Lesotho, Malawi, South Africa
Routine screening and treatment of TB and HIV patients in endemic countries can increase detection of co-infection and increase patient survival.
Tuberculosis
3 studies Gray II, IIIb TB, screening, treatment Brazil, Rwanda, Sub-Saharan Africa